Exagen (XGN) announced the appointment of Dr. Michael Mahler as Chief Scientific Officer. Over the course of his career, Dr. Mahler has held key positions at various diagnostic companies, most recently serving as Senior Vice President of Research Development and Business Development at Werfen. In his new role at Exagen, Dr. Mahler will spearhead strategic initiatives aimed at enhancing precision diagnostics for autoimmune diseases.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XGN: